S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
S&P 500   3,840.72
DOW   31,113.15
QQQ   322.58
Log in
OTCMKTS:CYTR

CytRx Stock Forecast, Price & News

$2.51
+0.11 (+4.58 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.10
Now: $2.51
$2.54
50-Day Range
$0.71
MA: $1.45
$2.42
52-Week Range
$0.35
Now: $2.51
$2.75
Volume279,825 shs
Average Volume245,948 shs
Market Capitalization$91.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
CytRx Corporation, a biopharmaceutical company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
CytRx logo

MarketRank

Overall MarketRank

0.56 out of 5 stars

Medical Sector

1371st out of 1,928 stocks

Biological Products, Except Diagnostic Industry

156th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYTR
CUSIPN/A
Phone310-826-5648
Employees4

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.45 per share

Profitability

Net Income$-7,160,000.00

Miscellaneous

Market Cap$91.56 million
Next Earnings Date2/15/2021 (Estimated)
OptionableOptionable
$2.51
+0.11 (+4.58 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CytRx (OTCMKTS:CYTR) Frequently Asked Questions

How has CytRx's stock price been impacted by COVID-19 (Coronavirus)?

CytRx's stock was trading at $0.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYTR stock has increased by 709.7% and is now trading at $2.51.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than CytRx?

Wall Street analysts have given CytRx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CytRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CytRx's next earnings date?

CytRx is scheduled to release its next quarterly earnings announcement on Monday, February 15th 2021.
View our earnings forecast for CytRx
.

How were CytRx's earnings last quarter?

CytRx Co. (OTCMKTS:CYTR) issued its quarterly earnings data on Monday, November, 16th. The biotechnology company reported ($0.08) EPS for the quarter.
View CytRx's earnings history
.

When did CytRx's stock split? How did CytRx's stock split work?

Shares of CytRx reverse split on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

Are investors shorting CytRx?

CytRx saw a increase in short interest in December. As of December 31st, there was short interest totaling 67,700 shares, an increase of 35.1% from the December 15th total of 50,100 shares. Based on an average daily trading volume, of 290,100 shares, the days-to-cover ratio is currently 0.2 days.
View CytRx's Short Interest
.

Who are some of CytRx's key competitors?

What other stocks do shareholders of CytRx own?

Who are CytRx's key executives?

CytRx's management team includes the following people:
  • Mr. Steven A. Kriegsman, Chairman & CEO (Age 78, Pay $1.05M)
  • Mr. John Y. Caloz, CFO & Treasurer (Age 68, Pay $500k)
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 57)

What is CytRx's stock symbol?

CytRx trades on the OTCMKTS under the ticker symbol "CYTR."

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $2.51.

How big of a company is CytRx?

CytRx has a market capitalization of $91.56 million and generates $250,000.00 in revenue each year. CytRx employs 4 workers across the globe.

What is CytRx's official website?

The official website for CytRx is www.cytrx.com.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.